菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics and Virogen Biotechnology Establish Commercial Manufacturing Partnership
June 9, 2025
WuXi Biologics and Virogen Biotechnology Establish Commercial Manufacturing Partnership

Chengdu, June 9, 2025 – WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic collaboration with Virogen Biotechnology Inc. (Virogen). Under the agreement, WuXi Biologics will provide comprehensive services, including technology transfer, process validation, and commercial manufacturing of both drug substance (DS) and drug product (DP) for VG712, Virogen’s lead clinical-stage asset. The partnership is expected to accelerate VG712’s path to global market approval.

 

 

VG712 is a first-in-class anti-CD3 immunotoxin designed to restore immune function through rapid depletion of the patient’s existing T cell pool—a novel therapeutic strategy known as immunological reset. By targeting T cell dysregulation, which lies at the core of cancers, autoimmune diseases, and other conditions, this groundbreaking approach allows the immune system to regenerate from a clean slate and regain its innate ability to control disease, offering the new hope for sustained remission and, in some cases, a clinical cure. Leveraging its end-to-end microbial fermentation platform, industry-leading DS and DP manufacturing capabilities, and world-class quality systems, WuXi Biologics will enable Virogen to advance VG712 from late-stage development to commercial-scale production. VG712 has received Fast Track designation from the U.S. Food and Drug Administration (FDA), and a pivotal Phase II trial is currently underway. A Biologics License Application (BLA) submission is targeted between 2027 and 2028, aiming to address significant unmet medical needs.

 

Dr. Chris Chen, CEO of WuXi Biologics, stated: “We are delighted to partner with Virogen on this groundbreaking therapy which further demonstrates our capabilities in enabling the Research, Development, and Manufacturing of complex molecules through our integrated microbial fermentation platform. The construction of our Chengdu microbial manufacturing site marks a significant expansion of our global network, allowing us to deliver more agile, efficient, and scalable solutions to our partners. In addition, we can bring more strategic resources to Virogen throughout its development journey. Together, we aspire to drive new breakthroughs in immunotherapy and bring renewed hope to patients worldwide.”

 

Su Chen, Founder of Virogen, commented: “This collaboration marks a major milestone for Virogen. WuXi Biologics’ strong track record in translating innovative science into commercial therapies makes it an ideal partner as we prepare for VG712’s global launch. We remain committed to delivering transformative treatments in immunotherapy that can truly save lives.”

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

 

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

 

Business

info@wuxibiologics.com

 

Media

PR@wuxibiologics.com

 

 

About Virogen Biotechnology

   
Virogen is a clinical stage biotechnology company with expertise in both US and Asia.  Its leading development program is VG712, invented at NIH by a pioneer in immunotoxin, Dr. David Neville.  Unlike earlier generation immunotoxins, VG712 induces a rapid and transient T cell depletion without triggering cytokine response.  By targeting CD3 receptors, VG712 is effective against all T cell subtypes.  Virogen owns the global rights to develop and commercialize this novel fusion protein and has completed the CMC development of drug products for global clinical trials.  

 

For more information visit virogenbio.com.